Advertisement
Advertisement

ARQT

ARQT logo

Arcutis Biotherapeutics, Inc. Common Stock

24.58
USD
Sponsored
-0.51
-2.03%
Apr 15, 16:00 UTC -4
Closed
exchange

After-Market

24.62

+0.04
+0.18%

Arcutis Biotherapeutics, Inc. Common Stock Profile

About

Arcutis Biotherapeutics Inc. is late-stage biopharmaceutical company. It is focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases. The company's product pipeline consists of ARQ-151, ARQ-154 and ARQ-252 for multiple indications, including psoriasis, atopic dermatitis, seborrheic dermatitis and eczema, which are in clinical stage. Arcutis Biotherapeutics Inc. is based in Westlake Village, California.

Info & Links

CEO

Todd Franklin Watanabe

Headquarters

3027 TOWNSGATE ROAD, SUITE 300
WESTLAKE VILLAGE, CA 91361, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.arcutis.com

Auditor

Ernst & Young LLP

Share holders

56

Employees

354

Arcutis Biotherapeutics, Inc. Common Stock Statistics

Valuation Measures

Market Capitalization2

3.05B

Enterprise Value

3.12B

Enterprise Value/EBITDA(ttm)

-323.18

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

8.10

Price to Book(mrq)

15.88

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

89.90%

Operating Margin(ttm)

-4.29%

Profit Margin(ttm)

-9.16%

Return on Equity(ttm)

-10.26%

Return on Invested Capital(ttm)

-7.83%

Return on Assets(ttm)

-4.30%

Income Statement

Revenue(ttm)

376.07M

Revenue Per Share(ttm)

3.03

Gross Profit(ttm)

339.38M

EBITDA(ttm)3

-9.65M

Net Income Available to Common(ttm)

-16.14M

Diluted EPS(ttm)

-0.14

Share Statistics

Beta (5Y Monthly)

1.76

52-Week Change

89.95%

S&P 500 52-Week Change

30.14%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

124.03M

Dividend Yield

0.00%

Float4

112.37M

% Held by Insiders

9.40%

% Held by Institutions

--

Balance Sheet

Total Cash(mrq)

221.29M

Total Cash Per Share(mrq)

1.78

Total Debt(mrq)

108.96M

Total Debt/Equity(mrq)

57.50%

Current Ratio(mrq)

3.17%

Quick Ratio(mrq)

2.99%

Book Value Per Share(mrq)

1.54

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.04

Free Cash Flow(ytd)

-6.31M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement